This
report provides comprehensive information on the therapeutic
development for Dilated Cardiomyopathy, complete with comparative
analysis at various stages, therapeutics assessment by drug target,
mechanism of action (MoA), route of administration (RoA) and molecule
type, along with latest updates, and featured news and press releases.
It also reviews key players involved in the therapeutic development for
Dilated Cardiomyopathy and special features on late-stage and
discontinued projects.
This report features
investigational drugs from across globe covering over 20 therapy areas
and nearly 3,000 indications. The report is built using data and
information sourced from the proprietary databases,
Company/University websites, SEC filings, investor presentations and
featured press releases from company/university sites and
industry-specific third party sources, put together by team members. Drug profiles/records featured in the report undergoes
periodic updation following a stringent set of processes that ensures
that all the profiles are updated with the latest set of information.
Additionally, processes including live news & deals tracking,
browser based alert-box and clinical trials registries tracking ensure
that the most recent developments are captured on a real time basis.
The
report enhances decision making capabilities and help to create
effective counter strategies to gain competitive advantage. It
strengthens R&D pipelines by identifying new targets and MOAs to
produce first-in-class and best-in-class products.
Scope
- The report provides a snapshot of the global therapeutic landscape of Dilated Cardiomyopathy
-
The report reviews key pipeline products under drug profile section
which includes, product description, MoA and R&D brief, licensing
and collaboration details & other developmental activities
- The
report reviews key players involved in the therapeutics development for
Dilated Cardiomyopathy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
-
A review of the Dilated Cardiomyopathy products under development by
companies and universities/research institutes based on information
derived from company and industry-specific sources
- Pipeline
products coverage based on various stages of development ranging from
pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Dilated Cardiomyopathy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
-
Provides strategically significant competitor information, analysis,
and insights to formulate effective R&D development strategies
-
Identify emerging players with potentially strong product portfolio and
create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Dilated Cardiomyopathy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
-
Devise corrective measures for pipeline projects by understanding
Dilated Cardiomyopathy pipeline depth and focus of Indication
therapeutics
- Develop and design in-licensing and out-licensing
strategies by identifying prospective partners with the most attractive
projects to enhance and expand business potential and scope
- Modify
the therapeutic portfolio by identifying discontinued projects and
understanding the factors that drove them from pipeline
Companies Mentioned
Array BioPharma Inc.
Kasiak Research Pvt. Ltd.
Sanofi
Vericel Corporation
Zensun (Shanghai) Sci & Tech Co., Ltd.
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home